You have 9 free searches left this month | to do more
Showing 1 - 25 of
2,829 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Not yet recruiting
  • MDS
  • AML
  • (no location specified)
2021-12-22
Dec 22, 2021
U
Decitabine and Talazoparib in Untreated AML and R/R AML
Active, not recruiting
  • Acute Myeloid Leukemia
  • Baltimore, Maryland
    University of Maryland Greenebaum Comprehensive Cancer Center
2021-10-05
Oct 5, 2021
M
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) - 2021
Terminated
Has Results
  • AML Including AML de Novo and AML Secondary to MDS
  • DLBCL
  • Birabresib Dose 20 mg
  • (no location specified)
2021-09-29
Sep 29, 2021
H
Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis
Recruiting
  • AML
  • Hyperleukocytosis
  • Monterrey, Nuevo Leon, Mexico
    Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitari
2021-10-09
Oct 9, 2021
M
Diagnosis and Treatment of Periodontal Disease in Patients With AML
Not yet recruiting
  • AML
  • Acute Myelogenous Leukemia
  • Scaling and Root Planing
  • (no location specified)
2021-08-03
Aug 3, 2021
C
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Not yet recruiting
  • AML
  • Gemtuzumab ozogamicine - Cytarabine - Gilteritinib
  • (no location specified)
2022-01-05
Jan 5, 2022
H
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation
Recruiting
  • AML
  • CAR-γδT
  • Yanda, Hebei, China
    Hebei yanda Ludaopei Hospital
2021-03-11
Mar 11, 2021
H
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Active, not recruiting
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
2021-09-01
Sep 1, 2021
T
NK Cell Therapy Recurrent/Refractory Elderly AML
Not yet recruiting
  • AML
  • +3 more
  • Allogeneic NK cell regimen group
  • Jinan, Shandong, China
    The 2nd Hospital of Shandong University
2020-10-21
Oct 21, 2020
A
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
Withdrawn
  • AML
  • APVO436
  • (no location specified)
2021-11-29
Nov 29, 2021
U
Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.
Recruiting
  • Acute Myeloid Leukemia
  • No intervention
  • Angers, France
    Angers University Hospital
2021-06-14
Jun 14, 2021
U
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.
Recruiting
  • AML, Adult
  • Berne, Switzerland
    Departement of Medical Oncology, University Hospital Berne
2021-07-29
Jul 29, 2021
T
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
Active, not recruiting
  • AML
  • FLT3-ITD Mutation
  • Hong Kong, Hong Kong
    The University of Hong Kong
2020-12-09
Dec 9, 2020
D
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Recruiting
  • Leukemia
  • Boston, Massachusetts
  • +1 more
2021-08-23
Aug 23, 2021
U
Cardioprotection in AML
Not yet recruiting
  • AML
  • Acute Myeloid Leukemia
  • Charlottesville, Virginia
    University of Virginia
2021-07-19
Jul 19, 2021
H
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Recruiting
  • Myeloid Malignancy
  • Detroit, Michigan
    Henry ford hospital
2021-12-23
Dec 23, 2021
H
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
Recruiting
  • AML
  • Venetoclax 100 MG
  • +2 more
  • Monterrey, Nuevo LEON, Mexico
    Andres Gomez
2021-09-07
Sep 7, 2021
D
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
Recruiting
  • Acute Myeloid Leukemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-10-04
Oct 4, 2021
S
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Recruiting
  • Acute Myeloid Leukemia (AML)
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Disease Hospital
2021-06-21
Jun 21, 2021
D
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Recruiting
  • Acute Myelogenous Leukemia
  • Boston, Massachusetts
  • +1 more
2021-11-15
Nov 15, 2021
B
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Active, not recruiting
  • Acute Myelogenous Leukemia
  • AML
  • DC AML Vaccine
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
2021-08-01
Aug 1, 2021
S
Phase 1 Study of Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • San Francisco, California
    Stanford University
2022-01-10
Jan 10, 2022
F
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS - 2019
Terminated
Has Results
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Philadelphia, Pennsylvania
  • +1 more
2021-02-22
Feb 22, 2021
P
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
Recruiting
  • AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
  • MRD-triggered arm
  • Prophylactic Arm
  • Heidelberg, BW, Germany
    University Hospital Heidelberg Med5
2021-01-04
Jan 4, 2021
C
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
Recruiting
  • Acute Myeloid Leukemia
  • Daunorubicin Cytarabine liposome for injection
  • Vyxeos、Daunorubicin Cytarabine liposome for injection
  • Tianjin, China
    Institute of Hematology and Hospital of Blood Disease, Chinese A
2021-06-07
Jun 7, 2021